Pharmacological validation of candidate causal sleep genes identified in an N2 cross

Joseph I. Brunner*, Anthony L. Gotter, Joshua Millstein, Susan Garson, Jacquelyn Binns, Steven V. Fox, Alan T. Savitz, He S. Yang, Karrie Fitzpatrick, Lili Zhou, Joseph R. Owens, Andrea L. Webber, Martha H. Vitaterna, Andrew Kasarskis, Victor N. Uebele, Fred Turek, John J. Renger, Christopher J. Winrow

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Despite the substantial impact of sleep disturbances on human health and the many years of study dedicated to understanding sleep pathologies, the underlying genetic mechanisms that govern sleep and wake largely remain unknown. Recently, the authors completed large-scale genetic and gene expression analyses in a segregating inbred mouse cross and identified candidate causal genes that regulate the mammalian sleep-wake cycle, across multiple traits including total sleep time, amounts of rapid eye movement (REM), non-REM, sleep bout duration, and sleep fragmentation. Here the authors describe a novel approach toward validating candidate causal genes, while also identifying potential targets for sleep-related indications. Select small-molecule antagonists and agonists were used to interrogate candidate causal gene function in rodent sleep polysomnography assays to determine impact on overall sleep architecture and to evaluate alignment with associated sleep-wake traits. Significant effects on sleep architecture were observed in validation studies using compounds targeting the muscarinic acetylcholine receptor M3 subunit (Chrm3) (wake promotion), nicotinic acetylcholine receptor alpha4 subunit (Chrna4) (wake promotion), dopamine receptor D5 subunit (Drd5) (sleep induction), serotonin 1D receptor (Htr1d) (altered REM fragmentation), glucagon-like peptide-1 receptor (Glp1r) (light sleep promotion and reduction of deep sleep), and calcium channel, voltage-dependent, T type, alpha 1I subunit (Cacna1i) (increased bout duration of slow wave sleep). Taken together, these results show the complexity of genetic components that regulate sleep-wake traits and highlight the importance of evaluating this complex behavior at a systems level. Pharmacological validation of genetically identified putative targets provides a rapid alternative to generating knock out or transgenic animal models, and may ultimately lead towards new therapeutic opportunities.

Original languageEnglish (US)
Pages (from-to)167-181
Number of pages15
JournalJournal of Neurogenetics
Volume25
Issue number4
DOIs
StatePublished - Dec 1 2011

Keywords

  • Genetics
  • Pharmacology
  • Rodent
  • Sleep
  • Translation

ASJC Scopus subject areas

  • Genetics
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Pharmacological validation of candidate causal sleep genes identified in an N2 cross'. Together they form a unique fingerprint.

  • Cite this

    Brunner, J. I., Gotter, A. L., Millstein, J., Garson, S., Binns, J., Fox, S. V., Savitz, A. T., Yang, H. S., Fitzpatrick, K., Zhou, L., Owens, J. R., Webber, A. L., Vitaterna, M. H., Kasarskis, A., Uebele, V. N., Turek, F., Renger, J. J., & Winrow, C. J. (2011). Pharmacological validation of candidate causal sleep genes identified in an N2 cross. Journal of Neurogenetics, 25(4), 167-181. https://doi.org/10.3109/01677063.2011.628426